Company profile
Oryzon Genomics SA
Pioneering personalized medicine in epigenetics
- Industry
- Biotechnology
- Employees
- 60
- Headquarters
- Cornellà de Llobregat, Catalonia
- Founded
- 2000
- LinkedIn followers
- 11,849
- Office locations
- 2
Oryzon Genomics SA company summary
Oryzon Genomics SA is a company in the Biotechnology industry, headquartered in Cornellà de Llobregat, Catalonia, founded in 2000. On LinkedIn the company has around 60 employees and 11,849 followers. The company lists 2 office locations. Its listed specialties include Drug discovery and development, biomarker discovery, cancer, neurodegeneration, epigenetics.
What technology does Oryzon Genomics SA use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Oryzon Genomics SA
Oryzon Genomics (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology/hematology. Founded in 2000 and headquartered in Barcelona, Spain, Oryzon brings together a highly experienced team accross Barcelona, Boston, and New Jersey. The Company’s clinical portfolio is built around two differentiated LSD1 inhibitors. Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials, with very promising efficacy signals in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented at ASH 2025, with additional data expected at EHA 2026. Vafidemstat, its lead CNS candidate, is in clinical development across neuropsychiatric indications, including aggression in borderline personality disorder (Phase III in preparation), negative symptoms of schizophrenia (ongoing Phase IIb) and aggression in autism spectrum disorder (ASD), including genetically defined populations such as Phelan-McDermid syndrome (Phase II in preparation). Beyond LSD1, Oryzon is expanding its pipeline to new targets such as HDAC6, with ORY-4001 nominated for potential development in neurological diseases including ALS and CMT. Oryzon also leverages a robust biomarker platform supporting precision medicine approaches. The Company is listed on the Spanish Stock Exchange (ORY) and has attracted specialized international investors from the United States and Europe.
Specialties
Where is Oryzon Genomics SA located?
Oryzon Genomics SA lists 2 office locations.
Compare companies similar to Oryzon Genomics SA
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Oryzon Genomics SA oryzon.com | Biotechnology | 60 | 2000 | Cornellà de Llobregat, Catalonia |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about Oryzon Genomics SA
What does Oryzon Genomics SA do?
Oryzon Genomics (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology/hematology. Founded in 2000 and headquartered in Barcelona, Spain, Oryzon brings together a highly experienced team accross Barcelona, Boston, and New Jersey. The Company’s clinical portfolio is built around two differentiated LSD1 inhibitors. Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials, with very promising efficacy signals in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented at ASH 2025, with additional data expected at EHA 2026. Vafidemstat, its lead CNS candidate, is in clinical development across neuropsychiatric indications, including aggression in borderline personality disorder (Phase III in preparation), negative symptoms of schizophrenia (ongoing Phase IIb) and aggression in autism spectrum disorder (ASD), including genetically defined populations such as Phelan-McDermid syndrome (Phase II in preparation). Beyond LSD1, Oryzon is expanding its pipeline to new targets such as HDAC6, with ORY-4001 nominated for potential development in neurological diseases including ALS and CMT. Oryzon also leverages a robust biomarker platform supporting precision medicine approaches. The Company is listed on the Spanish Stock Exchange (ORY) and has attracted specialized international investors from the United States and Europe.
How many employees does Oryzon Genomics SA have?
Oryzon Genomics SA has around 60 employees on LinkedIn.
Where is Oryzon Genomics SA headquartered?
Oryzon Genomics SA is headquartered in Cornellà de Llobregat, Catalonia.
Where does Oryzon Genomics SA have offices?
Oryzon Genomics SA lists 2 office locations, including Cornellà de Llobregat, Catalonia, ES; Boston, Massachusetts, US.
When was Oryzon Genomics SA founded?
Oryzon Genomics SA was founded in 2000.
Build a lead list from companies like Oryzon Genomics SA
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.